New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.
about
Six months therapy for abdominal tuberculosisShort-course versus prolonged-course antituberculous treatment in tuberculous meningitisTuberculosis 2015: Burden, Challenges and Strategy for Control and Elimination.Combating Tuberculosis Infection: A Forbidding ChallengeNew agents for the treatment of drug-resistant Mycobacterium tuberculosisTranslational Research for Tuberculosis Elimination: Priorities, Challenges, and ActionsEmerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Current trends and intricacies in the management of HIV-associated pulmonary tuberculosisSix months therapy for tuberculous meningitisCurrent strategies to treat tuberculosisRecent Developments and Future Opportunities in the Treatment of Tuberculosis in ChildrenDevelopment of a Nafion/MWCNT-SPCE-Based Portable Sensor for the Voltammetric Analysis of the Anti-Tuberculosis Drug EthambutolNeglected tropical diseases in the genomics era: re-evaluating the impact of new drugs and mass drug administrationIn silico evaluation and exploration of antibiotic tuberculosis treatment regimensAuranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasisSubstrate-analogous inhibitors exert antimalarial action by targeting the Plasmodium lactate transporter PfFNT at nanomolar scaleSix-month therapy for abdominal tuberculosis.Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.Classic reaction kinetics can explain complex patterns of antibiotic action.Are bigger data sets better for machine learning? Fusing single-point and dual-event dose response data for Mycobacterium tuberculosisDelamanid: a review of its use in patients with multidrug-resistant tuberculosis.A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis.Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis.A novel protein kinase inhibitor IMB-YH-8 with anti-tuberculosis activityMycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter studyCoincident helminth infection modulates systemic inflammation and immune activation in active pulmonary tuberculosis.Profile of delamanid for the treatment of multidrug-resistant tuberculosisAnti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery.Single-cell tracking reveals antibiotic-induced changes in mycobacterial energy metabolism.Mycobacterial nicotinate mononucleotide adenylyltransferase: structure, mechanism, and implications for drug discovery.Drug-resistance mechanisms and tuberculosis drugsA sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosetsTotal synthesis of tetraacylated phosphatidylinositol hexamannoside and evaluation of its immunomodulatory activity.Respiratory Infections in the U.S. Military: Recent Experience and ControlDesign, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents.Orofacial tuberculosis: Clinical manifestations, diagnosis and management.Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment.Determining the mode of action of anti-mycobacterial C17 diyne natural products using expression profiling: evidence for fatty acid biosynthesis inhibition.Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Combined Species Identification and Drug Sensitivity Testing in Mycobacteria.
P2860
Q24185961-18E318B7-A9A4-44A3-AACF-65D8F60F7BA9Q24186210-D4C8BF9B-45CA-4979-9E52-B094F691D073Q26741136-7A49331A-568E-467A-9C37-D20DF265EF30Q26750683-872D328B-B6F6-419C-8BCE-C30941CDBF11Q26751463-F60D641B-F67A-40EC-B6D2-3F1D28A8A443Q26765051-5440ED38-A7AC-4DE1-BD53-EB06260AA5C9Q26771997-A8371756-3258-44A2-ADAF-CE9AE4ACE3E5Q28069032-B438624F-D308-4EF0-B2E7-B8E0C7BB143EQ28074247-60B254E0-BA68-4934-8222-ABF472F00409Q28075252-DA2ACC50-0804-46CC-8B2A-167304FFA9C4Q28085210-F2B750A5-581A-4120-825F-DDA5593FE5EAQ28385702-FB5B70BB-2A9A-4405-9E99-1DA9D10EE545Q28602660-B880FCC0-628D-4F12-ADF2-2DF95E01B5D8Q28607283-B9D3C71D-7548-44F7-9DCE-0B29948A4DD5Q29013419-9190367A-8D50-491B-BCE7-633C3F9ACB34Q30042971-83C58D37-BA4B-4826-9690-CFF4C792149CQ30242077-E012E5E6-F655-4DA1-8362-67FCA149A4BDQ30275673-B3D0C115-C40C-4CB6-ACDC-18AF6E4423E0Q30373724-E999C12E-38AC-4FD0-9889-FDEBE7056B5AQ30662980-66C7E150-9063-41AC-9F19-3652FBD9709CQ30833510-28012E21-24B5-402A-A45D-62D56CF59B15Q33164956-8DA61D40-637C-4766-A118-DB6A6A32BA32Q33626683-DC77284F-955E-4B95-AFB5-6A832967AFB0Q33801345-8D49B5C2-C1DE-4100-A1C9-991865E50266Q33894977-8AA53DC7-9779-4982-94F7-EEBEF2BCF481Q34420149-6B62BAC1-049B-4997-993F-BB89C618A97FQ34465369-FD835D9C-3606-4817-B0E9-F6C84FE8E6D1Q35057495-579BDFD6-6B2C-44D1-9488-1F4987C312E4Q35090116-887E82C0-1A6C-4A39-BFF0-F769F70756C2Q35115383-2F55FAEA-2C99-47DA-A48F-AD1439DC932CQ35199412-9D4F2315-72C5-46D9-B49D-F933A0CB8E1DQ35218108-306E59AA-E4AB-4246-B808-E31B7053CD6CQ35745991-97328270-DBE6-498C-9B99-4F9C9312B4A7Q35746591-166A9E1C-4FD6-46FD-8711-99A0F752EA6EQ35763405-6578460A-1998-47C8-8B64-09DE3DC4910DQ35844546-04F9122C-A51D-40BC-8C37-C8598ED81B26Q35949004-9D852F80-2900-4F9F-A64C-D749A417B0CDQ36082913-9A69309A-4FA4-4D15-81EE-63FB4B32ACF2Q36101770-8C3DCCB0-910E-45D3-BC02-DCFE9A69B5A0Q36230810-1C11F588-EB00-4860-8C36-22C08CAF3F0A
P2860
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
New antituberculosis drugs, re ...... dvances, and future prospects.
@en
type
label
New antituberculosis drugs, re ...... dvances, and future prospects.
@en
prefLabel
New antituberculosis drugs, re ...... dvances, and future prospects.
@en
P2093
P50
P1476
New antituberculosis drugs, re ...... dvances, and future prospects.
@en
P2093
Andrew J Nunn
Marco Schito
Patrick P J Philips
Stewart T Cole
P304
P356
10.1016/S1473-3099(13)70328-1
P50
P577
2014-04-01T00:00:00Z